Table 1.

Baseline characteristics of patients before and after propensity score‐matched cohort

	Before PSM		P	After PSM		P
	S n = 605 (%)	PORT n = 387 (%)		S n = 311 (%)	PORT n = 311 (%)
Sex			0.361			0.316
Female	140 (23.1)	80 (20.7)		57 (18.3)	67 (21.5)
Male	465 (76.9)	307 (79.3)		254 (81.7)	244 (78.5)
Age (years)			<0.001			0.868
≤60	297 (49.1)	268 (69.3)		199 (64)	197 (63.3)
>60	308 (50.9)	119 (30.7)		112 (36)	114 (36.7)
Vascular carcinomatous thrombi			0.277			0.204
No	527 (87.1)	346 (89.4)		262 (84.2)	273 (87.8)
Yes	78 (12.9)	41 (10.6)		49 (15.8)	38 (12.2)
Differentiation			0.077			0.767
Well	89 (14.7)	62 (16.0)		46 (14.8)	46 (14.8)
Moderate	375 (62.0)	213 (55.0)		168 (54.0)	176 (56.6)
Poor	141 (23.3)	112 (29.0)		97 (31.2)	89 (28.6)
Tumor location			<0.001			0.864
Upper	42 (6.9)	64 (16.5)		36 (11.6)	36 (11.6)
Medium	366 (60.5)	223 (57.6)		179 (57.6)	185 (59.5)
Lower	197 (32.6)	100 (25.8)		96 (30.9)	90 (28.9)
T stage			<0.001			0.86
T1	35 (5.8)	29 (7.5)		31 (10.0)	26 (8.4)
T2	103 (17.0)	74 (19.1)		60 (19.3)	63 (20.3)
T3	445 (73.6)	236 (61.0)		203 (65.3)	202 (65.0)
T4a	22 (3.6)	48 (12.4)		17 (5.5)	20 (6.4)
T stage category			0.173			0.86
T1–2	138 (22.8)	103 (26.6)		91 (29.3)	89 (28.6)
T3–4a	467 (77.2)	284 (73.4)		220 (70.7)	222 (71.4)
N = 1			<0.001			0.334
T1	30 (7.5)	15 (6.5)		29 (13.4)	15 (8.0)
T2	72 (17.9)	53 (22.8)		43 (19.8)	44 (23.5)
T3	287 (71.4)	136 (58.6)		135 (62.2)	118 (63.1)
T4a	13 (3.2)	28 (12.1)		10 (4.6)	10 (5.3)
N = 2			0.001			0.211
T1	5 (2.5)	14 (9)		2 (2.1)	11 (8.9)
T2	31 (15.3)	21 (13.5)		17 (18.1)	19 (15.3)
T3	158 (77.8)	100 (64.5)		68 (72.3)	84 (67.7)
T4a	9 (4.4)	20 (12.9)		7 (7.4)	10 (8.1)
Eighth AJCC stage			0.35			0.771
IIB (T1N1)	35 (5.8)	29 (7.5)		31 (10.0)	26 (8.4)
IIIA (T2N1)	103 (17.0)	74 (19.1)		60 (19.3)	63 (20.3)
IIIB (T3–4N1)	467 (77.2)	284 (73.4)		220 (70.7)	222 (71.4)